ClinicalTrials.gg
CompletedNCT05844228Updated Oct 16, 2026Results posted

A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

A Phase 1 interventional study of VIR-2218 in Renal Impairment, sponsored by Vir Biotechnology, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Vir Biotechnology, Inc. · Phase 1, Interventional, and Treatment

Updated Oct 16, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
267th of 468
28 · median 32
Started
2023
with 20 others
Phase 1
232 of 553
14 open now
Registered
485th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 267th largest by enrollment of the 468 interventional ones that give a count, is one of 21 that started in 2023, is one of 232 in phase 1, and was the 485th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal renal function and participants with varying degrees of renal dysfunction who are otherwise medically stable

Read the detailed description

Participants may be enrolled in Cohorts 1 and 2 in a non-randomized way.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for All Participants:

  • Participants must have stable renal function as defined by less than 20% change in estimated (eGFR) between the first and second screening sample with the first screening visit occurring within 28 days prior to dosing on Day 1 and the second screening visit occurring no more than 14 days apart, but at least 72 hours apart from the first.
  • (BMI) within the range 18.5 to 40.0 kg/m\^2 at screening.
  • Female and Male participants must consent to follow requirements
  • Capability of giving signed form

Inclusion Criteria: Additional Criteria Specific to Healthy Participants:

  • Must be in the opinion of the investigator, be in good health based upon medical history, vital signs, physical examination, and screening laboratory evaluations
  • Must have normal renal function as defined by eGFR ≥ 90 mL/min/1.73m\^2 based on the Modification of Diet in Renal Disease (MDRD) equation determined from the mean of two measurements of serum creatinine at screening.

Inclusion Criteria: Additional Criteria Specific to Participants with Renal Impairment

  • Participants must, in the opinion of the investigator, be sufficiently healthy for study participation based on medical history, physical examination, vital signs, and screening laboratory evaluations
  • Participants with RI must have chronic moderate or severe RI and be clinically stable per investigator assessment for at least 3 months prior to screening
  • Moderate RI as defined by eGFR level 30-59 mL/min/1.73m\^2 based on the MDRD equation, or
  • Severe RI as defined by eGFR level 15-29mL/min/1.73m\^2 based on the MDRD equation

Exclusion Criteria: Criteria for All Participants

  • Any medical condition or psychiatric condition that may interfere with study intervention
  • Participants with uncontrolled hypertension, asthma, and/or diabetes (Type I or II).
  • Participants with diabetes
  • Participants with any active
  • Participants with vasculitis or conditions associated with vasculitis.
  • Participants who have undergone major surgery within 12 months of screening
  • Participants with unstable cardiac functions, abnormality, or clinically significant heart failure
  • Participants with infection of , HAV, , , HDV, or HEV
  • Participants with signs of active infection
  • History of bone marrow or solid organ transplantation
  • Participants with end-stage renal disease or nephrotic syndrome as defined by: participants requiring hemodialysis or peritoneal dialysis, participants who have undergone or are listed for transplant, or participants who have chronic kidney disease with nephrotic syndrome
  • Participants with active nephritis
  • Participants with clinically significant liver disease
  • History of drug or alcohol abuse
  • Unwillingness or inability to follow procedures outlined in protocol

Exclusion Criteria: Additional Criteria Specific to Healthy Participants

  • Use of any prescription medications or over-the-counter medications (with the exception of vitamins and/or hormonal contraceptive medications) including herbal products within 30 days prior to D1 of study participation

Exclusion Criteria: Additional Criteria Specific to Participants with Renal Impairment

  • Not on stable dose and regimen of any medication(s) (prescription or over-the-counter) that the participants is taking regularly (eg, medications for chronic conditions such as hypertension, high cholesterol, or depression must not be changed in dose or type for at least 2 weeks prior to study drug administration). Use of other prescription medications or over-the-counter medications that are not for chronic conditions (with the exception of vitamins and/or hormonal contraceptive medications) including herbal products within 30 days prior to D1 of study participation
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Cohort 1: Up to 8 moderate Renal Impairment participants and up to 8 matched healthy participants

    Drug: VIR-2218

  • Experimental
    Cohort 2: Up to 8 severe Renal Impairment participants and up to 8 matched healthy participants

    Drug: VIR-2218

Interventions

  • VIR-2218 given by subcutaneous injection

    Also known as: Elebsiran

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218

    Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.

    Time frame: 4 days

  2. Area Under The Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218

    Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.

    Time frame: 4 days

  3. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218

    Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.

    Time frame: 4 days

  4. Fraction Excreted in Urine in Percentage for VIR-2218

    Time frame: 4 days

  5. Amount Excreted in Urine for VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218

    Time frame: 4 days

  6. Renal Clearance for VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218

    Time frame: 4 days

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: 8 weeks

07

Results

Posted Oct 16, 2026
Limitations and caveats
In Cohort 1, there was one race mismatch between a patient with moderate RI (White) and their matched healthy counterpart (Black). An ad hoc analysis was performed to compare the resulting PK parameters with or without the mismatched pair.

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: Single Dose of VIR-2218 in Moderate Renal Impairment and Matched Healthy ParticipantsCohort 2: Singe Dose of VIR-2218 in Severe Renal Impairment and Matched Healthy Participants
Started1612
Completed1612
Not completed00

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218

Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.

Time frame:
4 days
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
ng/mLCohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment ParticipantsCohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched ParticipantsCohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment ParticipantsCohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants
VIR-2218 Cmax319 ± 31.4390 ± 13.2584 ± 32.6488 ± 19.9
AS(N-1)3'VIR-2218 Cmax44.7 ± 42.449.5 ± 31.691.7 ± 52.359.3 ± 33.6
PrimaryArea Under The Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218

Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.

Time frame:
4 days
Reported as:
Geometric mean · h*ng/mL
Area Under The Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
h*ng/mLCohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment ParticipantsCohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched ParticipantsCohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment ParticipantsCohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants
VIR-2218 AUClast7140 ± 28.16590 ± 24.411100 ± 47.38240 ± 19.0
AS(N-1)3'VIR-2218 AUClast1050 ± 34.2812 ± 39.42020 ± 49.31080 ± 20.9
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218

Pharmacokinetic samples were collected at -2 hours pre-dose and at 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours post-dose.

Time frame:
4 days
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
h*ng/mLCohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment ParticipantsCohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched ParticipantsCohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment ParticipantsCohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants
VIR-2218 AUCinf7550 ± 31.76670 ± 30.311300 ± 47.28530 ± 19.0
AS(N-1)3'VIR-2218 AUCinf1240 ± 35.31110 ± 46.02740 ± 36.21220 ± 29.0
PrimaryFraction Excreted in Urine in Percentage for VIR-2218
Time frame:
4 days
Reported as:
Geometric mean · fe%
Fraction Excreted in Urine in Percentage for VIR-2218
fe%Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment ParticipantsCohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched ParticipantsCohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment ParticipantsCohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants
Fraction Excreted in Urine in Percentage for VIR-22189.18 ± 35.812.6 ± 36.64.96 ± 50.715.9 ± 30.1
PrimaryAmount Excreted in Urine for VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Time frame:
4 days
Reported as:
Geometric mean · mg
Amount Excreted in Urine for VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
mgCohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment ParticipantsCohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched ParticipantsCohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment ParticipantsCohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants
VIR-2218 Ae18.4 ± 35.825.3 ± 36.69.91 ± 50.731.9 ± 30.1
AS(N-1)3'VIR-2218 Ae4.09 ± 41.04.11 ± 36.12.22 ± 42.95.14 ± 31.0
PrimaryRenal Clearance for VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
Time frame:
4 days
Reported as:
Geometric mean · L/h
Renal Clearance for VIR-2218 and Its Metabolite AS(N-1)3'VIR-2218
L/hCohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment ParticipantsCohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched ParticipantsCohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment ParticipantsCohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants
VIR-2218 CLR2.57 ± 20.23.83 ± 50.60.891 ± 76.93.87 ± 29.0
AS(N-1)3'VIR-2218 CLR3.90 ± 19.85.06 ± 46.91.10 ± 79.34.78 ± 35.2
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
8 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsCohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment ParticipantsCohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched ParticipantsCohort 2: Singe Dose of VIR-2218 in up to 8 Severe Renal Impairment ParticipantsCohort 2: Singe Dose of VIR-2218 in up to 8 Healthy Matched Participants
Participants with any TEAEs2052
Participants with any SAEs0000

Adverse events

Collected over Up to 12 weeks. Non-serious events are listed at a 1.25% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment Participants0/8 (0%)0/8 (0%)2/8 (25%)
Cohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched Participants0/8 (0%)0/8 (0%)0/8 (0%)
Cohort 2: Singe Dose of VIR-2218 in 6 Severe Renal Impairment Participants0/6 (0%)0/6 (0%)5/6 (83.3%)
Cohort 2: Singe Dose of VIR-2218 in 6 Healthy Matched Participants0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventCohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment ParticipantsCohort 1: Singe Dose of VIR-2218 in 8 Healthy Matched ParticipantsCohort 2: Singe Dose of VIR-2218 in 6 Severe Renal Impairment ParticipantsCohort 2: Singe Dose of VIR-2218 in 6 Healthy Matched Participants
Urinary tract infectionInfections and infestations1/80/81/60/6
Alanine aminotransferase increasedInvestigations0/80/80/61/6
AnaemiaBlood and lymphatic system disorders0/80/81/60/6
ConstipationGastrointestinal disorders0/80/81/60/6
Fibrin D dimer increasedInvestigations0/80/81/60/6
HyperkalaemiaMetabolism and nutrition disorders0/80/81/60/6
Injection site haematomaGeneral disorders0/80/81/60/6
Muscle strainMusculoskeletal and connective tissue disorders0/80/81/60/6
Upper respiratory tract infectionInfections and infestations0/80/80/61/6
CrystalluriaRenal and urinary disorders1/80/80/60/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment ParticipantsCohort 1: Single Dose of VIR-2218 in 8 Healthy Matched ParticipantsCohort 2: Single Dose of VIR-2218 in 6 Severe Renal Impairment ParticipantsCohort 2: Single Dose of VIR-2218 in 6 Healthy Matched ParticipantsTotal
Participant Age — <=18 years00000
Participant Age — Between 18 and 65 years275519
Participant Age — >=65 years61119
Age, Continuous
Age, Continuous(years)Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment ParticipantsCohort 1: Single Dose of VIR-2218 in 8 Healthy Matched ParticipantsCohort 2: Single Dose of VIR-2218 in 6 Severe Renal Impairment ParticipantsCohort 2: Single Dose of VIR-2218 in 6 Healthy Matched ParticipantsTotal
Cohort 1 Participant Ages64.6 ± 5.7160.4 ± 4.24——62.5 ± 5.33
Cohort 2 Participant Ages——59.8 ± 6.5557.2 ± 6.8258.5 ± 6.53
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment ParticipantsCohort 1: Single Dose of VIR-2218 in 8 Healthy Matched ParticipantsCohort 2: Single Dose of VIR-2218 in 6 Severe Renal Impairment ParticipantsCohort 2: Single Dose of VIR-2218 in 6 Healthy Matched ParticipantsTotal
Female664420
Male22228
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment ParticipantsCohort 1: Single Dose of VIR-2218 in 8 Healthy Matched ParticipantsCohort 2: Single Dose of VIR-2218 in 6 Severe Renal Impairment ParticipantsCohort 2: Single Dose of VIR-2218 in 6 Healthy Matched ParticipantsTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American23117
White655521
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment ParticipantsCohort 1: Single Dose of VIR-2218 in 8 Healthy Matched ParticipantsCohort 2: Single Dose of VIR-2218 in 6 Severe Renal Impairment ParticipantsCohort 2: Single Dose of VIR-2218 in 6 Healthy Matched ParticipantsTotal
United States886628
Weight
Weight(kg)Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment ParticipantsCohort 1: Single Dose of VIR-2218 in 8 Healthy Matched ParticipantsCohort 2: Single Dose of VIR-2218 in 6 Severe Renal Impairment ParticipantsCohort 2: Single Dose of VIR-2218 in 6 Healthy Matched ParticipantsTotal
Cohort 1 Weight94.7 ± 12.8279.2 ± 5.3——86.9 ± 12.38
Cohort 2 Weight——98.5 ± 10.6478.2 ± 6.6488.3 ± 13.57
BMI
BMI(kg/m^2)Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment ParticipantsCohort 1: Single Dose of VIR-2218 in 8 Healthy Matched ParticipantsCohort 2: Single Dose of VIR-2218 in 6 Severe Renal Impairment ParticipantsCohort 2: Single Dose of VIR-2218 in 6 Healthy Matched ParticipantsTotal
Cohort 1 BMI31.2 ± 2.9629.2 ± 3.32——30.2 ± 3.20
Cohort 2 BMI——32.0 ± 3.6330.0 ± 4.7231.0 ± 4.15
eGFR
eGFR(mL/min/1.73 m^2)Cohort 1: Single Dose of VIR-2218 in 8 Moderate Renal Impairment ParticipantsCohort 1: Single Dose of VIR-2218 in 8 Healthy Matched ParticipantsCohort 2: Single Dose of VIR-2218 in 6 Severe Renal Impairment ParticipantsCohort 2: Single Dose of VIR-2218 in 6 Healthy Matched ParticipantsTotal
Cohort 1 eGFR49.38 ± 4.069108.25 ± 17.244——78.81 ± 32.724
Cohort 2 eGFR——22.83 ± 4.579100 ± 100.50761.42 ± 41.033
08

Study locations

3 sites
  • Inland Empire Clinical Trials
    Rialto, California 92377, United States
  • Floridian Clinical Research
    Miami Lakes, Florida 33016, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Mar 2025, 21 months.

Results were first posted in Oct 2026, 1 year 7 months after primary completion.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 21 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2023
First posted
May 6, 2023
StartActual
Jun 1, 2023
Primary completionActual
Mar 1, 2025
CompletionActual
Apr 21, 2025
Results first posted
Oct 16, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 16, 2026
Interventions
Arm changed Cohort 1: Up to 8 moderate Renal Impairment (RI) participants and 8 matched healthy participants→Cohort 1: Up to 8 moderate Renal Impairment participants and up to 8 matched healthy participants; Cohort 2: Up to 8 severe Renal Impairment (RI) participants and 6 matched healthy participants→Cohort 2: Up to 8 severe Renal Impairment participants and up to 8 matched healthy participants
Oct 16, 2026
Primary outcomes
6 edited
What changed in the outcomes
  • EditedMaximum Observed Plasma Concentration (Cmax) of VIR-2218 and its metaboliteIts Metabolite AS(N-1)3'VIR-2218Time frame: 5 days → 4 days
  • EditedArea Under The Plasma Concentration-time Curve fromFrom Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and its metaboliteIts Metabolite AS(N-1)3'VIR-2218Time frame: 5 days → 4 days
  • EditedArea Under the Plasma Concentration-time Curve fromFrom Time Zero to Infinity (AUCinf) of VIR-2218 and its metaboliteIts Metabolite AS(N-1)3'VIR-2218Time frame: 5 days → 4 days
  • EditedFraction excretedExcreted in urineUrine in percentagePercentage for VIR-2218 and its metabolite AS(N-1)3'VIR-2218Time frame: 5 days → 4 days
  • EditedAmount excretedExcreted in urineUrine for VIR-2218 and its metaboliteIts Metabolite AS(N-1)3'VIR-2218Time frame: 5 days → 4 days
  • EditedRenal clearanceClearance for VIR-2218 and its metaboliteIts Metabolite AS(N-1)3'VIR-2218Time frame: 5 days → 4 days
Oct 16, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of participants with treatmentParticipants With Treatment-emergent adverse eventsAdverse Events (TEAEs) and serious adverse eventsSerious Adverse Events (SAEs)Time frame: Up to 12 weeks → 8 weeks
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Results posted
    Primary outcomes 6 edited
    What changed in the outcomes
    • EditedMaximum Observed Plasma Concentration (Cmax) of VIR-2218 and its metaboliteIts Metabolite AS(N-1)3'VIR-2218Time frame: 5 days → 4 days
    • EditedArea Under The Plasma Concentration-time Curve fromFrom Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and its metaboliteIts Metabolite AS(N-1)3'VIR-2218Time frame: 5 days → 4 days
    • EditedArea Under the Plasma Concentration-time Curve fromFrom Time Zero to Infinity (AUCinf) of VIR-2218 and its metaboliteIts Metabolite AS(N-1)3'VIR-2218Time frame: 5 days → 4 days
    • EditedFraction excretedExcreted in urineUrine in percentagePercentage for VIR-2218 and its metabolite AS(N-1)3'VIR-2218Time frame: 5 days → 4 days
    • EditedAmount excretedExcreted in urineUrine for VIR-2218 and its metaboliteIts Metabolite AS(N-1)3'VIR-2218Time frame: 5 days → 4 days
    • EditedRenal clearanceClearance for VIR-2218 and its metaboliteIts Metabolite AS(N-1)3'VIR-2218Time frame: 5 days → 4 days
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of participants with treatmentParticipants With Treatment-emergent adverse eventsAdverse Events (TEAEs) and serious adverse eventsSerious Adverse Events (SAEs)Time frame: Up to 12 weeks → 8 weeks
    Interventions Arm changed Cohort 1: Up to 8 moderate Renal Impairment (RI) participants and 8 matched healthy participants→Cohort 1: Up to 8 moderate Renal Impairment participants and up to 8 matched healthy participants; Cohort 2: Up to 8 severe Renal Impairment (RI) participants and 6 matched healthy participants→Cohort 2: Up to 8 severe Renal Impairment participants and up to 8 matched healthy participants
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05844228
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Jun 1, 2023
Primary completion
Mar 1, 2025
Completion
Apr 21, 2025
Results posted
Oct 16, 2026
Last update
Oct 16, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elebsiran

Start the discussion